Treatment with a single drug targeting a specific receptor is no longer considered optimal in the treatment and management of complex diseases such as HIV/AIDS, diabetes, and cardiovascular N. Pourkavoos () Novo Nordisk A/S,
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First-Tier Category: Improvement of Activity and/or Tolerability
Drugs in the combination product have different mechanisms of action often with a single aim such that the therapeutic effect is either improved or broadened with a side-effect profile similar to that of respective monotherapies given at the same or higher dose. For example a recent study found that the triple-drug combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension was very effective, safe, and well tolerated by patients [8] . Other recent clinical reviews of new drug medications include effectiveness and safety of two drug combinations for type 2 diabetes [9] and for dyslipidemia and obesity treatment in metabolic syndrome [10] . Alternatively, tolerance of a lowdose combination of drugs is improved with similar therapeutic effectiveness over respective higher dose monotherapies [11] . 
Second-Tier Category: Improvement in

Symptomatic and Pharmacokinetic Profile
These combinations may contain at least one component not previously approved for an indication. The intensity and duration of action of monotherapy is increased by combining with a second component that reduces the metabolic inactivation or elimination of the [13, 14] .
Inherent Risks of Combination Products
Selection of the Most Appropriate Therapeutic Agents
Arguably the foremost risk factor is in the 
Loss of Therapeutic Flexibility
Another risk is loss of therapeutic flexibility for titration. 
Patient Compliance and Impact of
Personalized Medicine
From the patient's perspective, polypharmacy and the complexity of the medication regimen are important factors for noncompliance [17] .
The incentive for simplification of therapy is to improve compliance and adherence to medication in order to improve health outcomes [18] . The relationship between adherence to ARV combination regimen and development of drug-resistant viral mutations and replication was reviewed by Bangsberg et al. [19] .
The National Council on Patient Information and Education has estimated that because of poor adherence between 30-50% of prescriptions fail to produce the desired therapeutic results in patients with chronic medical conditions [20] .
Several studies in compliance literature have provided data to support this theory [21, 22] .
Bangalore et al. [23] 
MArKEt sHIFts AND DrIVErs
It is well recognized that the overall costs for given in Table 5 [36, 55, [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] . [16] .
Preclinical Safety Pharmacology
Considerations
The need for preclinical toxicology data may 
